Clinical and pharmacokinetic evaluation of satraplatin

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 1, 2012, Pages 103-111

  Doshi, Gury ^a   Sonpavde, Guru ^a,b   Sternberg, Cora N ^c  

^a TEXAS ONCOLOGY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

JM 216; Oral platinum; Pharmacokinetics; Prostate cancer; Satraplatin

Indexed keywords

BEVACIZUMAB; BRCA1 PROTEIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROPYRIMIDINE; FOLINIC ACID; GEMCITABINE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; PREDNISONE; SATRAPLATIN; UFT;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; BRAIN TUMOR; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; COLORECTAL CANCER; DIARRHEA; DRUG ABSORPTION; DRUG ACTIVATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; GASTROINTESTINAL SYMPTOM; GERM CELL TUMOR; GROUPS BY AGE; HUMAN; HYPERGLYCEMIA; INFECTION; KIDNEY DYSFUNCTION; LIPOPHILICITY; LUNG CANCER; LUNG SMALL CELL CANCER; LYMPHOCYTOPENIA; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OTOTOXICITY; OVARY CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; THORAX CANCER; THROMBOCYTOPENIA; UROGENITAL TRACT TUMOR; VOMITING;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION; HUMANS; NEOPLASMS; ORGANOPLATINUM COMPOUNDS;

EID: 84255167302     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.636352     Document Type: Review

References (74)

1. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7(8):573-84 (Pubitemid 47106628)
2. Kelland L. Broadening the clinical use of platinum drug-based chemotherapy with new analogues. Satraplatin and picoplatin. Expert Opin Investig Drugs 2007;16(7):1009-21 (Pubitemid 47074157)
3. Taylor AE, Wiltshaw E, Gore ME, et al. Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J Clin Oncol 1994;12(10):2066-70 (Pubitemid 24356022)
4. Skarlos DV, Samantas E, Kosmidis P, et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 1994;5(7):601-7 (Pubitemid 24283096)
5. Horwich A, Sleijfer DT, Fossa SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997;15(5):1844-52 (Pubitemid 27209513)
6. Galsky MD, Chen GJ, Oh WK, et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol 2011 May 4; [Epub ahead of print]
7. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007;99(11):847-57
8. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18(16):2938-47 (Pubitemid 30644117)
9. McKeage MJ, Morgan SE, Boxall FE, et al. Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents. Br J Cancer 1993;67(5):996-1000 (Pubitemid 23147491)
10. McKeage MJ, Boxall FE, Jones M, Harrap KR. Lack of neurotoxicity of oral bisacetatoamminedichlorocyclohexy lamine-platinum(IV) in comparison to cisplatin and tetraplatin in the rat. Cancer Res 1994;54(3):629-31
11. McKeage MJ, Kelland LR, Boxall FE, et al. Schedule dependency of orally administered bis-acetato-amminedichloro-cyclohexylamine-platinum(IV) (JM216) in vivo. Cancer Res 1994;54(15):4118-22
12. Kelland LR, Abel G, McKeage MJ, et al. Preclinical antitumor evaluation of bisacetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res 1993;53(11):2581-6 (Pubitemid 23168026)
13. Mellish KJ, Kelland LR, Harrap KR. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Br J Cancer 1993;68(2):240-50 (Pubitemid 23229419)
14. Twentyman PR, Wright KA, Mistry P, et al. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin. Cancer Res 1992;52(20):5674-80
15. Wosikowski K, Lamphere L, Unteregger G, et al. Preclinical antitumor activity of the oral platinum analog satraplatin. Cancer Chemother Pharmacol 2007;60(4):589-600 (Pubitemid 47084271)
16. Mellish KJ, Barnard CF, Murrer BA, Kelland LR. DNA-binding properties of novel cis-and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines. Int J Cancer 1995;62(6):717-23
17. Perry J, Powles T, Shamash J, et al. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines. Cancer Chemother Pharmacol 2009;64(5):925-33
18. Mellish KJ, Kelland LR. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bisacetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines. Cancer Res 1994;54(23):6194-200 (Pubitemid 24378653)
19. Rose WC. Combination chemotherapy involving orally administered etoposide and JM-216 in murine tumor models. Cancer Chemother Pharmacol 1997;40(1):51-6 (Pubitemid 27160960)
20. Rose WC, Crosswell AR, Schurig JE, Casazza AM. Preclinical antitumor activity of orally administered platinum (IV) complexes. Cancer Chemother Pharmacol 1993;32(3):197-203 (Pubitemid 23146812)
21. Kelland LR. An update on satraplatin: the first orally available platinum anticancer drug. Expert Opin Investig Drugs 2000;9(6):1373-82 (Pubitemid 30342621)
22. Choy H, Park C, Yao M. Current status and future prospects for satraplatin, an oral platinum analogue. Clin Cancer Res 2008;14(6):1633-8 (Pubitemid 351469447)
23. Sova P, Mistr A, Kroutil A, et al. A comparative study of pharmacokinetics, urinary excretion and tissue distribution of platinum in rats following a single-dose oral administration of two platinum(IV) complexes LA-12 (OC-6-43)-bis(acetato) (1-adamantylamine) amminedichloroplatinum(IV) and satraplatin (OC-6-43)-bis(acetato) amminedichloro(cyclohexylamine) platinum(IV). Cancer Chemother Pharmacol 2011;67(6):1247-56
24. Poon GK, Raynaud FI, Mistry P, et al. Metabolic studies of an orally active platinum anticancer drug by liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr A 1995;712(1):61-6
25. Sharp SY, Rogers PM, Kelland LR. Transport of cisplatin and bis-acetatoammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance. Clin Cancer Res 1995;1(9):981-9
26. Marcus L, Murphy R, Fox E, et al. The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates. Cancer Chemother Pharmacol 2011 Jun 26; [Epub ahead of print]
27. ONeill CF, Koberle B, Masters JR, Kelland LR. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin. Br J Cancer 1999;81(8):1294-303
28. Kostrhunova H, Kasparkova J, Gibson D, Brabec V. Studies on cellular accumulation of satraplatin and its major metabolite JM118 and their interactions with glutathione. Mol Pharm 2010;7(6):2093-102
29. Raynaud FI, Odell DE, Kelland LR. Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels. Br J Cancer 1996;74(3):380-6 (Pubitemid 26254566)
30. Kostrhunova H, Vrana O, Suchankova T, et al. Different features of the DNA binding mode of antitumor cis-amminedichlorido(cyclohexylamine) platinum(II) (JM118) and cisplatin in vitro. Chem Res Toxicol 2010;23(11):1833-42
31. Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996;56(21):4881-6 (Pubitemid 26374423)
32. McKeage MJ. Satraplatin in hormone-refractory prostate cancer and other tumour types: pharmacological properties and clinical evaluation. Drugs 2007;67(6):859-69 (Pubitemid 46607387)
33. Samimi G, Kishimoto S, Manorek G, et al. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin. Cancer Chemother Pharmacol 2007;59(3):301-12 (Pubitemid 46025517)
34. Ando Y, Shimizu T, Nakamura K, et al. Potent and non-specific inhibition of cytochrome P450 by JM216, a new oral platinum agent. Br J Cancer 1998;78(9):1170-4 (Pubitemid 28479146)
35. McKeage MJ, Mistry P, Ward J, et al. A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Pharmacol 1995;36(6):451-8
36. McKeage MJ, Raynaud F, Ward J, et al. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 1997;15(7):2691-700 (Pubitemid 27289902)
37. Beale P, Raynaud F, Hanwell J, et al. Phase I study of oral JM216 given twice daily. Cancer Chemother Pharmacol 1998;42(2):142-8 (Pubitemid 28267295)
38. Sessa C, Minoia C, Ronchi A, et al. Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days. Ann Oncol 1998;9(12):1315-22 (Pubitemid 29045571)
39. Vouillamoz-Lorenz S, Buclin T, Lejeune F, et al. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days. Anticancer Res 2003;23(3C):2757-65 (Pubitemid 36969812)
40. Ricart AD, Sarantopoulos J, Calvo E, et al. Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study. Clin Cancer Res 2009;15(11):3866-71
41. Galsky MD, Camacho LH, Chiorean EG, et al. Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors. Ann Oncol 2011 Aug 9; [Epub ahead of print]
42. Jones S, Hainsworth J, Burris HA III, et al. Phase I study of JM-216 (an oral platinum analogue) in combination with paclitaxel in patients with advanced malignancies. Invest New Drugs 2002;20(1):55-61 (Pubitemid 34251651)
43. DeMario MD, Ratain MJ, Vogelzang NJ, et al. A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine- dichlorocyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days. Cancer Chemother Pharmacol 1999;43(5):385-8 (Pubitemid 29120248)
44. Choy H, Hughes RS, Dimaio M, et al. Phase I study of oral platinum with concurrent radiation therapy in non small cell lung cancer. J Clin Oncol 2008;26(20 Suppl):abstract 7560
45. Cmelak AJ, Choy H, Murphy BA, et al. Phase I study of JM-216 with concurrent radiation in non-small cell lung cancer and squamous cell head and neck cancer. J Clin Oncol 1999;abstract 1520,18:393a
46. Gallerani E, Bauer J, Hess D, et al. A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies. Acta Oncol 2011 Oct; 50(7):1105-10
47. Cetnar J, Wilding G, McNeel D, et al. A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer. Urologic oncology
48. Deshpande HA, Gettinger S, Rowen E, et al. A phase I study investigating the combination of orally bioavailable platinum and nanoparticle albumin-bound paclitaxel in advanced solid tumors. J Clin Oncol 2009;27(Suppl):abstract e13501
49. Di Paola ED, Alonso S, DAlessio A, et al. Dose finding study of the combination of satraplatin and gemcitabine in patients with advanced solid tumors. J Clin Oncol 2009;27(Suppl):abstract e13534
50. Fokkema E, Groen HJ, Bauer J, et al. Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. J Clin Oncol 1999;17(12):3822-7
51. Fokkema E, de Vries EG, Meijer S, Groen HJ. Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients. Cancer Chemother Pharmacol 2000;45(1):89-92 (Pubitemid 30099722)
52. Judson I, Cerny T, Epelbaum R, et al. Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation. Ann Oncol 1997;8(6):604-6 (Pubitemid 127746494)
53. Thompson DS, Spigel DR, Hainsworth JD, et al. Phase II trial of satraplatin (S) and paclitaxel (P) in first-line advanced non-small cell lung cancer (NSCLC) treatment: final results. J Clin Oncol 2008;26(20 Suppl):abstract 19023
54. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346(2):92-8 (Pubitemid 34438899)
55. Smith JW II, McIntyre KJ, Acevedo PV, et al. Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer. Breast Cancer Res Treat 2009;118(2):361-7
56. Latif T, Wood L, Connell C, et al. Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC). Invest New Drugs 2005;23(1):79-84 (Pubitemid 39505954)
57. Vaishampayan UN, Heilbrun L, Dickow B, et al. Phase II trial of bevacizumab (B) and oral satraplatin (S) and prednisone in docetaxel pretreated metastatic castrate resistant prostate cancer (CRPC). J Clin Oncol 2011;29(Suppl 7):abstract 152.
58. Galsky MD, Seng S, Camacho LH, et al. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy. Clin Genitourin Cancer 2011;9(1):27-30
59. Trudeau M, Stuart G, Hirte H, et al. A phase II trial of JM-216 in cervical cancer: an NCIC CTG study. Gynecol Oncol 2002;84(2):327-31 (Pubitemid 34136788)
60. Canobbio L, Guarneri D, Miglietta L, et al. Carboplatin in advanced hormone refractory prostatic cancer patients. Eur J Cancer 1993;29A(15):2094-6 (Pubitemid 23348122)
61. Miglietta L, Cannobbio L, Boccardo F. Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity. Anticancer Res 1995;15(6B):2825-8 (Pubitemid 26095107)
62. Trump DL, Marsh JC, Kvols LK, et al. A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy. An Eastern Cooperative Oncology Group pilot study. Invest New Drugs 1990;8(Suppl 1):S91-4 (Pubitemid 20174298)
63. Oh WK, Tay MH, Huang J. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? Cancer 2007;109(3):477-86 (Pubitemid 46190955)
64. Ross RW, Beer TM, Jacobus S, et al. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer 2008;112(3):521-6 (Pubitemid 351186193)
65. Oh WK, Halabi S, Kelly WK, et al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer 2003;98(12):2592-8 (Pubitemid 37509522)
66. Sternberg CN, Whelan P, Hetherington J, et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005;68(1):2-9 (Pubitemid 40675002)
67. Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009;27(32):5431-8
68. Korn EL, Freidlin B, Abrams JS. Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. J Clin Oncol 2011;29(17):2439-42
69. Wheate NJ, Walker S, Craig GE, Oun R. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans 2010 Sep 21; 39(35):8113-27
70. Ciuleanu T, Samarzjia M, Demidchik Y, et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy. J Clin Oncol 2010;28(Suppl 15s):abstract 7002
71. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355(10):983-91 (Pubitemid 44343542)
72. Soria JC. ERCC1-tailored chemotherapy in lung cancer: the first prospective randomized trial. J Clin Oncol 2007;25(19):2648-9
73. Ruzzo A, Graziano F, Loupakis F, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 2007;25(10):1247-54 (Pubitemid 46640571)
74. Huang RS, Johnatty SE, Gamazon ER, et al. Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res 2011;17(16):5490-500